OCUP News and Press, Ocuphire Pharma Inc Com From 08/03/22

Ophthalmology-focused Ocuphire Pharma ( NASDAQ: OCUP ) announced on Wednesday the issuance of a new U.S. patent for its lead candidate Nyxol eye drops that could extend the IP rights for the eye disease candidate. Nyxol is a once-daily, eye drop formulation of phentolamine...

Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication Growing Patent Estate Eligible for FDA Orange Book Listing On Track to File NDA for Nyxol in First Indication RM in Late 2022 Potential Second Half 2023 Approval as ...

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11 th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking Paper Highlighting Data from Two Phase 3 Registration Trials in Reversal of Mydriasis for Nyxol Second AS...

Ocuphire Pharma ( NASDAQ: OCUP ) on Wednesday said it had got a new U.S. patent extending the expiry and broadening the coverage of the company's late-stage oral product candidate APX3330. The U.S. Patent and Trademark Office issued patent no 11,351,130 to OCUP for APX...

Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication Highlights the Critical Role of Inflammation Regulator NFkB as a Target for Ref-1 inhibition Using APX3330 and APX Pipeline ...

Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks Topline Results with First-in-Class Non-Invasive Retinal Candidate APX3330 Expected in Second Half of 2022 Mina Sooch CEO to Participate in Ophthalmology Panel ...

Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...

Vinco Ventures (BBIG) -14%. Cisco Systems (CSCO) -12% on Q3 earnings release. Decisionpoint Systems (DPSI) -10%. Ocuphire Pharma (OCUP) -10% despite main goal met for Nyxol late-stage trial for night vision disturbances. Kohl's (KSS) -9% on Q1 earnings relea...

Ocuphire Pharma (NASDAQ:OCUP), a clinical-stage biotech focused on eye diseases, announced on Thursday that its Phase 3 pivotal clinical trial for Nyxol met the FDA-agreed primary endpoint in patients with the night (or dim light) vision disturbances (NVD). According to the topline data, the ...

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial for the Large Unmet Need of Treating Night Vision Disturbances (NVD) in Subjects...